PERSONALIZED PATHWAY-ACTIVATED SYSTEMS IMAGING IN ONCOLOGY. PRINCIPAL AND INSTRUMENTATION

1. PET Radiotracers for Tumor Imaging
2. Theranostic Approaches for Pathway-Activated Systems in Oncology
3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP
4. OpenPET Enabling PET Imaging During Radiotherapy
5. High-Resolution PET/CT Development
6. Ethics, Regulations, and Clinical Development of Precision Medicine: Activating with Molecular Imaging
7. Optical Imaging: How Far Can We Go
8. Applications of UIH High-Resolution PET/CT in Zhongshan Hospital
9. Clinical Evaluation of Focused High-Resolution Breast PET
10. Recent Developments with Large-Bore PET/CT
11. Copper-Labeled Radiopharmaceuticals in Oncology
12. PET Radiopharmaceuticals in Oncology Beyond FDG
13. Molecular Imaging in Oncology: Challenges and Opportunities in the Twenty-First Century
14. Visualization of Apoptosis: Annexin V Imaging

This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed.
Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome.
This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.

Features
• Elucidates the benefits and pitfalls of current clinic FDG PET
• Enriches understanding of moving radiopharmaceuticals from the workbench to the clinic
• Provides translational research for clinical discussions about pathway directed systems imaging which correlates with genomic and proteomic expressions

Authors
• Dr. Tomio Inoue. President, Yokohama City University Medical Center
• Dr. David J. Yang. Professor and Section Chief, Radiotheranostic Section, Department of Cancer System Imaging, Division of Diagnostic Imaging, MD Anderson Cancer Center, Consultant and Professor at The University of Tennessee Health Science Center, Vice-president for Vyripharm Biopharmaceuticals
• Dr. Gang Huang. Chairman, Institute of Nuclear Medicine, Shanghai JiaoTong University School of Medicine